Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? (Q37362717)

19 August 2017

1 reference

title

Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? (English)

1 reference

19 August 2017

1 reference

Ashish Aneja

1

1 reference

19 August 2017

Michael E Farkouh

series ordinal

2

1 reference

19 August 2017

publication date

1 February 2008

1 reference

Therapeutic advances in cardiovascular disease

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

53-66

1 reference

Celecoxib for the prevention of sporadic colorectal adenomas

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Are all COX-2 inhibitors created equal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Physiological regulation of cyclooxygenase-2 in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Worsening heart failure associated with COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Cardiovascular risk of selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Renal complications of nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Which chronic conditions are associated with better or poorer quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Nonsteroidal anti-inflammatory drugs: effects on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707088184

21 January 2018

Identifiers

DOI

10.1177/1753944707088184

1 reference

19 August 2017

1 reference